Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
ABCL AbCellera Biologics
10.810-0.160-1.46%
Close
02/07 16:00 ET
10.820+0.010+0.09%
Post Mkt Price 02/07 16:32 ET
High
11.025
Open
10.940
Turnover
14.00M
Low
10.560
Pre Close
10.970
Volume
1.30M
Post-Market
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Jackson Creek Investment Advisors LLC Buys Shares of 83,634 AbCellera Biologics Inc. (NASDAQ:ABCL)
Jackson Creek Investment Advisors LLC bought a new stake in AbCellera Biologics Inc. (NASDAQ:ABCL – Get Rating) in the 3rd quarter, according to its most recent 13F filing with the Securities and Ex
AbCellera Biologics Inc. (NASDAQ:ABCL) Given Consensus Recommendation of "Buy" by Brokerages
AbCellera Biologics Inc. (NASDAQ:ABCL – Get Rating) has been assigned a consensus recommendation of "Buy" from the six brokerages that are currently covering the stock, MarketBeat Ratings reports. F
AbCellera Biologics Inc. (NASDAQ:ABCL) Shares Bought by ProShare Advisors LLC
ProShare Advisors LLC raised its holdings in AbCellera Biologics Inc. (NASDAQ:ABCL – Get Rating) by 3.1% during the third quarter, according to the company in its most recent Form 13F filing with th
Barclays PLC Lowers Stock Position in AbCellera Biologics Inc. (NASDAQ:ABCL)
Barclays PLC reduced its stake in shares of AbCellera Biologics Inc. (NASDAQ:ABCL – Get Rating) by 2.0% during the third quarter, according to the company in its most recent 13F filing with the Secu
Eli Lilly Slips as Falling Demand for COVID Therapy Hurts Topline
AbCellera to Present at the SVB Securities Global Biopharma Conference on February 15, 2023
AbCellera (NASDAQ:ABCL) today announced that it will present at the SVB Securities Global Biopharma Conference on Wednesday, February 15, 2023, at 10:00 a.m. Pacific Time (1:00 p.m. Eastern Time). A live audio webcast
AbCellera to Report Full Year 2022 Financial Results on February 21, 2023
AbCellera (NASDAQ:ABCL) will announce its full year 2022 financial results on Tuesday, February 21, 2023, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day. A live
Here's Why AbCellera Biologics (NASDAQ:ABCL) Has Caught The Eye Of Investors
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even companies that have no revenue, no profit, and a record of falling short, can manage
Prospect of Further Federal Reserve Interest Rate Increases Pressuring Exchange-Traded Funds, Equity Futures
08:44 AM EST, 01/24/2023 (MT Newswires) -- The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was 0.3% lower in premarket activity Tuesday and the actively traded Invesco QQQ Trust (QQ
AbCellera Biologics Clears Key Benchmark, Hitting 80-Plus RS Rating
AbCellera Biologics saw a positive improvement to its Relative Strength (RS) Rating on Monday, rising from 77 to 81. When looking for the best stocks to buy and watch, keep a close on eye on relative
Company Overview
More
AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Véronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.
CEO： Dr. Carl L.G. Hansen, PhD
Market： NASDAQ
Listing Date： 12/11/2020
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet